Association for Professionals in Infection Prevention and Epidemiology

June 12-14, 2019

Philadelphia, PA

Visit us at Booth #509

Join us for a Breakfast Symposium

Surgical Implant Infection: The Prevention Imperative
Speaker: Maureen Spencer, M.Ed, BSN, RN, CIC, FAPIC
Moderator: Sue Barnes, RN, CIC, FAPIC

EARN CE CREDIT: 1.8 CE certificate provided

Surgical Implant Infection: The Prevention Imperative

Aerobiotix Exhibitor Satellite Symposium
Friday, June 14, 2019
6:00 AM – 7:45 AM
Philadelphia Convention Center Room 204-C

EARN CE CREDIT: 1.8 CE certificate provided.

Speaker: Maureen Spencer, MEd, BSN, RN, CIC, FAPIC – Infection Prevention Consultant
Moderator: Sue Barnes, RN, BSN, CIC, FAPIC – Infection Prevention Consultant

Approximately 1.2 million arthroplasties are performed annually in the U.S., and that number is expected to increase to 3.8 million by the year 2030. But beyond orthopedic procedures, virtually all surgical disciplines are now engaged in implanting devices. This includes cardiac, general, spinal, and OB/GYN surgery. Infections associated with these implants are expensive in terms of patient suffering and financial impact on hospitals. The general estimate for the cost of a prosthetic joint infection (PJI) in the U.S. is approximately $100,000, but legal settlements have been known to drive costs far higher. And though the infection rate for PJI is low from 2.0-2.4%, infections associated with other types of implants are higher than average. For instance, implanted mesh infection following incisional hernia repair has been reported on average between 6-10%.

Over the last two decades a growing number of studies have shown evidence that airborne microbial populations play a significant role in the etiology of SSI and that procedures involving an implant are at significant risk after intraoperative contamination from even a minimal microbial inoculum.

This session will explore the correlation between the environment of the OR and infections involving implantable devices, with emphasis on the contribution of contaminated air, pathways for reduction of risk and new evidence on emerging technology shown to reduce aerosolized bioburden and SSI.

Save Your Seat!

Complete the form or call Ann at 1-800-978-7087, ext. 103.



Contact Us


444 Alexandersville Rd
Miamisburg, Ohio 45342
+1 888 978 7087



President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.


Vice President of Sales

Nathan brings a high level of commitment to servicing and building client relations. He was one of the first employees to start for Aerobiotix. Nathan has previously held leadership roles in the medical device industry. He received his BS from Antioch McGregor University Midwest.


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.